Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors
- Conditions
- Pancreas CancerHRD Positive Advanced Ovarian CancerBreast CancerOvarian CancerBRCA1 MutationProstate CancerBRCA-Mutated Ovarian CarcinomaBRCA-Associated Breast Carcinoma
- Interventions
- Registration Number
- NCT06065059
- Lead Sponsor
- Tango Therapeutics, Inc.
- Brief Summary
The goal of this interventional clinical trial is to learn about TNG348, a ubiquitin specific peptidase 1 (USP1) inhibitor, alone and in combination with olaparib in patients with BRCA 1/2 mutant or HRD+ solid tumors.
The main question\[s\] it aims to answer are:
* to evaluate the safety and tolerability of single agent and combination therapy
* to determine the recommended dose for Phase 2 of single agent and combination therapy
* to determine the pharmacokinetics of TNG348 as a single agent and in combination therapy
* to evaluate the initial antineoplastic activity as a single agent and in combination therapy
Participants will receive study treatment until they experience an undesirable side effect, their disease progresses or until they withdraw consent.
- Detailed Description
This is a first-in-human Phase 1/2, open-label, multi-center, dose-escalation and expansion study designed to determine the maximum-tolerated dose (MTD) and recommended Phase 2 dose(s) (RP2D) and evaluate the safety, tolerability, and preliminary antitumor activity of TNG348 single agent and in combination with olaparib in participants with BRCA1/2 mutant or other HRD+ advanced or metastatic solid tumors.
In Phase 1 (dose escalation), the single agent component will explore escalating oral doses of TNG348 administered alone and in combination with olaparib.
Participants in Phase 2 (dose expansion) will be dosed at the RP2D(s) determined from Phase 1 based on safety and tolerability demonstrated, along with the available PK data and studied during Phase 1, as applicable.
In the Phase 2 portion of the study, both single agent and combination therapy may be evaluated to assess an early signal of clinical benefit, as well as for confirmation of safety and tolerability.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 7
- Is ≥18 years of age at the time of signature of the main study ICF.
- Has ECOG performance status of 0 or 1.
- Has advanced or metastatic solid tumor with measurable disease based on RECIST v1.1.
- All participants must have documented BRCA 1/2 mutant or other HRD+ in solid tumor, which is identified through a validated sequencing test
- Adequate organ and bone marrow function per local labs
- Negative serum pregnancy test result at screening
- Written informed consent must be obtained according to local guidelines
- Known allergies, hypersensitivity, or intolerance to TNG348, olaparib or its excipients
- Uncontrolled intercurrent illness that will limit compliance with the study requirements
- Currently participating in or has planned participation in a study of another investigational agent or device
- Impairment of GI function or disease that may significantly alter the absorption of study drug
- Active prior or concurrent malignancy.
- Central nervous system metastases associated with progressive neurological symptoms
- Participant with MDS
- Clinically relevant cardiovascular disease
- Participant with known active or chronic infection
- A female patient who is pregnant or lactating
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description Single Agent Dose Escalation TNG348 Participants with BRCA 1/2 mutant or HRD+ solid tumors will receive escalating doses of TNG348 to estimate the MTD Combination Dose Escalation TNG348 Participants with BRCA 1/2 mutant or HRD+ solid tumors will receive escalating doses of TNG348 in combination with olaparib to estimate the MTD Combination Dose Escalation Olaparib Participants with BRCA 1/2 mutant or HRD+ solid tumors will receive escalating doses of TNG348 in combination with olaparib to estimate the MTD Single agent dose expansion in breast cancer TNG348 Participants with BRCA 1/2 mutant breast cancer will receive TNG348 at the identified RP2D Combination therapy dose expansion in breast cancer TNG348 Participants with BRCA 1/2 mutant breast cancer will receive TNG348 in combination with olaparib at the identified RP2D Combination therapy dose expansion in breast cancer Olaparib Participants with BRCA 1/2 mutant breast cancer will receive TNG348 in combination with olaparib at the identified RP2D Combination therapy dose expansion in ovarian cancer Olaparib Participants with BRCA 1/2 mutant ovarian cancer will receive TNG348 in combination with olaparib at the identified RP2D Combination therapy dose expansion in pancreatic or prostate cancer Olaparib Participants with BRCA 1/2 mutant pancreatic or prostate cancer will receive TNG348 in combination with olaparib at the identified RP2D Combination therapy dose expansion in HRD+ advanced or metastatic solid tumors TNG348 Participants with HRD+ advanced or metastatic solid tumors will receive TNG348 in combination with olaparib at the identified RP2D Combination therapy dose expansion in HRD+ advanced or metastatic solid tumors Olaparib Participants with HRD+ advanced or metastatic solid tumors will receive TNG348 in combination with olaparib at the identified RP2D Combination therapy dose expansion in pancreatic or prostate cancer TNG348 Participants with BRCA 1/2 mutant pancreatic or prostate cancer will receive TNG348 in combination with olaparib at the identified RP2D Single agent dose expansion in ovarian cancer TNG348 Participants with BRCA 1/2 mutant ovarian cancer will receive TNG348 at the identified RP2D Combination therapy dose expansion in ovarian cancer TNG348 Participants with BRCA 1/2 mutant ovarian cancer will receive TNG348 in combination with olaparib at the identified RP2D
- Primary Outcome Measures
Name Time Method To determine dosing for TNG348 alone and in combination (Phase 1 only) 21 days • To determine the MTD, RP2D(s), and dosing schedule of TNG348 single agent and in combination with olaparib
Measure anti-tumor activity using RECIST 1.1 (Phase 2 only) 56 days To assess the antitumor activity of TNG348 single agent and in combination using RECIST 1.1 per investigator assessment
- Secondary Outcome Measures
Name Time Method Characterize the safety and tolerability profile 21 days Measure frequency, severity, timing, and relationship to study treatment of any AEs, SAEs, and changes in safety laboratory tests
Characterize the plasma PK profile 16 days To determine the half-life of TNG348
Assess changes in levels of ubPCNA in response to TNG348 as single agent or in combination 22 days Measure ubPCNA in tumor tissue and blood, on study treatment relative to pre-treatment
Characterize olaparib concentrations when administered with TNG348 16 days To characterize the pre treatment and trough concentration levels of olaparib when administered in combination with TNG348
Measure anti-tumor activity using RECIST 1.1 (Phase 1 only) 56 days To assess the antitumor activity of TNG348 single agent and in combination using RECIST 1.1 per investigator assessment
Trial Locations
- Locations (7)
New York University Langone Health
🇺🇸New York, New York, United States
Mid Florida Cancer Centers
🇺🇸Orange City, Florida, United States
Florida Cancer Specialists
🇺🇸Sarasota, Florida, United States
The University of Texas MD Anderson Cancer Center
🇺🇸Houston, Texas, United States
HealthONE
🇺🇸Denver, Colorado, United States
Memorial Sloan Kettering Cancer Center
🇺🇸New York, New York, United States
Dana Farber Cancer Institute
🇺🇸Boston, Massachusetts, United States